Skip to main content
Premium Trial:

Request an Annual Quote

InforMax Reports Fallen Revenues, Receded R&D, and Narrowed Loss in Q3

NEW YORK, Oct. 30 - InforMax today reported a 35-percent fall-off in revenue atop decreased R&D spending and a narrowed net loss.

 

For the period ended Sept. 30, InforMax, which two weeks ago said it will be acquired by Invitrogen, had total receipts amounted to $3 million, down from $4.7 million reported during the same quarter one year ago.

 

R&D spending, like all operating expenses, fell in the third quarter to $2 million compared with $2.5 million year over year, InforMax said.

 

Consequently, the company said third-quarter net loss narrowed to $5.2 million, or $.20 per share, from $5.4 million, or $.22 per share, during the same period one year ago.

 

InforMax said it had roughly $46.9 million in cash, cash equivalents, and investments available for sale as of Sept. 30.

 

Click here for more information.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.